Sanofi SA, a French pharmaceutical company, will collaborate with Exscientia Plc, a British artificial intelligence company, to develop up to 15 therapeutic candidates in cancer and immunology in a contract worth up to US$5.2 billion in milestone payments, the two firms said on Friday.
Exscientia will receive a one-time payment of $100 million in exchange for leading the development and design of small molecule therapeutics up to the nomination of the most feasible candidate. Following that, Sanofi will be in charge of clinical development.
“Typically, we must synthesis 5,000 molecules before identifying the one that will become the clinical candidate. By utilizing AI, you may be able to do this by only looking at 500… As a result, timetables might be shortened “Sanofi worldwide head of research and chief scientific officer, Frank Nestle, stated.In November, the company paid 180 USD million for a 10% to 15% stake in Owkin, a French firm that uses predictive analytics to improve cancer research and development.